Intra-Cellular Therapies’ $460 Million Shares Offering

White & Case has advised J.P. Morgan Securities LLC, SVB Leerink LLC, BofA Securities, Inc., Evercore Group L.L.C. and RBC Capital Markets, LLC as representatives of the underwriters on the offering.

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) announced its US$460 million follow-on offering. The offering consisted of 10,952,381 shares of Intra-Cellular Therapies’ common stock at a public offering price of US$42.00 per share, which included 1,428,571 shares of common stock issued pursuant to the full exercise of the underwriters’ overallotment option. 

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel Prize–winning research that allows us to understand how therapies affect the inner workings of cells in the body. The company leverages this intra-cellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases.

The White & Case capital markets team was led by partner Stuart Bressman (Picture) and associates Alok Choksi, Christina Min and Joseph Chen (all in New York). The team also included partner Anita Varma in Boston, and associate Yang Xu in Silicon Valley (both Intellectual Property). 

Involved fees earner: Stuart Bressman – White & Case; Alok Choksi – White & Case; Christina Min – White & Case; Anita Varma – White & Case; Yang Xu – White & Case;

Law Firms: White & Case;

Clients: Bank of America Securities; Evercore Inc.; J.P. Morgan Securities LLC; RBC Capital Markets; SVB Leerink LLC;